Primary Sjögren's syndrome (pSS) is a chronic systemic inflammatory disease, which mainly affects the lacrimal and salivary glands, leading to sicca syndrome. pSS has a probable autoimmune etiology, with the production of several autoantibodies such as antinuclear antibodies (ANA), anti-Ro/SS-A, anti-La/SS-B, rheumatoid factor (RF) and cryoglobulins. Recently, our group described a high frequency of antibodies directed to DNase I in the serum of pSS patients and these antibodies were associated with the presence of the anti-Epstein-Barr (EBV) early antigen diffuse (anti-EA-D). This finding becomes interesting considering the recent description of reduction of DNase I activity in the tear of patients with xerophthalmia of different causes, which would result in an accumulation of extracellular DNA and neutrophilic inflammatory infiltrate on the ocular surface. This hypothesis is reinforced by the observation that treatment with DNase I as eye drops results in clinical improvement of dry eye. In addition, it has been shown that periodontal disease is an aggravating factor of xerostomia in pSS, as it leads to a chronic inflammatory process and, consequently, to the destruction of minor salivary glands. Therefore, the objective of the present study will be to evaluate the presence of antibodies directed to DNase I in the saliva and serum of pSS patients and its possible capacity of inhibition of the enzyme before and after treatment of periodontal disease. Such findings will be correlated with the presence of periodontal disease, with the glandular and extraglandular manifestations of SSp and also with the presence of EBV DNA in the serum and oral lavage of these patients.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
80
Periodontal scaling and root planing
Hospital das Clínicas da Faculdade de Medicina da USP
São Paulo, São Paulo, Brazil
Rheumatology Division of Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo
São Paulo, São Paulo, Brazil
Hospital das Clínicas da Faculdade de Medicina da USP
São Paulo, Brazil
Change from baseline Xerostomia Inventory Score at 3 months
Change from baseline Xerostomia Inventory Score at 3 months. An international validated questionnaire of dry mouth symptoms ranging from 11 to 55 points.
Time frame: Change from baseline Xerostomia Inventory Score at 3 months
Change from baseline activity of DNAse I enzyme in saliva at 3 months
Change from baseline activity of DNAse I enzyme in saliva at 3 months measured by Enzyme-Linked Immunosorbent Assay (ELISA).
Time frame: Change from baseline activity of DNAse I enzyme in saliva at 3 months
Change from baseline interleukin-1b (IL-1b) concentration in saliva at 3 months
Change from baseline interleukin-1b (IL-1b) concentration in saliva at 3 months measured by Luminex Assay.
Time frame: Change from baseline interleukin-1b (IL-1b) concentration in saliva at 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.